JP2021514395A5 - - Google Patents

Info

Publication number
JP2021514395A5
JP2021514395A5 JP2020566525A JP2020566525A JP2021514395A5 JP 2021514395 A5 JP2021514395 A5 JP 2021514395A5 JP 2020566525 A JP2020566525 A JP 2020566525A JP 2020566525 A JP2020566525 A JP 2020566525A JP 2021514395 A5 JP2021514395 A5 JP 2021514395A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
cell lymphoma
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566525A
Other languages
English (en)
Japanese (ja)
Other versions
JP7434185B2 (ja
JP2021514395A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018472 external-priority patent/WO2019164794A1/en
Publication of JP2021514395A publication Critical patent/JP2021514395A/ja
Publication of JP2021514395A5 publication Critical patent/JP2021514395A5/ja
Priority to JP2023087801A priority Critical patent/JP2023109974A/ja
Application granted granted Critical
Publication of JP7434185B2 publication Critical patent/JP7434185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566525A 2018-02-20 2019-02-19 三置換ベンゾトリアゾール誘導体の使用方法 Active JP7434185B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023087801A JP2023109974A (ja) 2018-02-20 2023-05-29 三置換ベンゾトリアゾール誘導体の使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2018/018679 2018-02-20
US2018018679 2018-02-20
PCT/US2019/018472 WO2019164794A1 (en) 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023087801A Division JP2023109974A (ja) 2018-02-20 2023-05-29 三置換ベンゾトリアゾール誘導体の使用方法

Publications (3)

Publication Number Publication Date
JP2021514395A JP2021514395A (ja) 2021-06-10
JP2021514395A5 true JP2021514395A5 (cg-RX-API-DMAC7.html) 2022-03-01
JP7434185B2 JP7434185B2 (ja) 2024-02-20

Family

ID=61692059

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566525A Active JP7434185B2 (ja) 2018-02-20 2019-02-19 三置換ベンゾトリアゾール誘導体の使用方法
JP2023087801A Pending JP2023109974A (ja) 2018-02-20 2023-05-29 三置換ベンゾトリアゾール誘導体の使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023087801A Pending JP2023109974A (ja) 2018-02-20 2023-05-29 三置換ベンゾトリアゾール誘導体の使用方法

Country Status (13)

Country Link
US (2) US11717512B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755324B1 (cg-RX-API-DMAC7.html)
JP (2) JP7434185B2 (cg-RX-API-DMAC7.html)
KR (1) KR102861339B1 (cg-RX-API-DMAC7.html)
CN (1) CN111757731B (cg-RX-API-DMAC7.html)
AU (1) AU2019223906B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016929A8 (cg-RX-API-DMAC7.html)
CA (1) CA3091792A1 (cg-RX-API-DMAC7.html)
ES (1) ES3038736T3 (cg-RX-API-DMAC7.html)
MA (1) MA51897A (cg-RX-API-DMAC7.html)
MX (1) MX2020008678A (cg-RX-API-DMAC7.html)
TW (1) TWI818954B (cg-RX-API-DMAC7.html)
WO (1) WO2019164794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3091792A1 (en) * 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
BR112021012305A2 (pt) 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas
CN111662872A (zh) * 2020-05-06 2020-09-15 西南医科大学附属医院 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法
US20230285364A1 (en) * 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9708620A (es) 1995-05-10 1998-02-28 Pfizer Combinacion de metotrexate y tenidap para el tratamiento de artritis reumatoide.
AU7622000A (en) 1999-10-01 2001-05-10 Institute Of Molecular And Cell Biology Compounds for the treatment of viral-mediated diseases
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
NZ588896A (en) * 2004-08-25 2012-05-25 Targegen Inc Heterocyclic compounds and methods of use
MX2007003375A (es) 2004-09-22 2007-05-07 Janssen Pharmaceutica Nv Inhibidores de la interaccion entre mdm2 y p53.
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
DE102005049953A1 (de) 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
KR101177729B1 (ko) 2006-09-08 2012-09-07 에프. 호프만-라 로슈 아게 벤조트리아졸 키나아제 조절제
WO2010081898A1 (en) 2009-01-19 2010-07-22 Neurosearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
US9316632B2 (en) 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
SG174125A1 (en) 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
WO2013049112A1 (en) 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
CN103965133B (zh) 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
ES2694829T3 (es) * 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6629840B2 (ja) 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
EP3344243B1 (en) * 2015-09-01 2020-12-09 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
MX2018008169A (es) 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
EP3858361B1 (en) 2018-09-28 2025-10-08 FUJIFILM Corporation Antitumor agent containing cytarabine, antitumor effect enhancer used in combination with cytarabine, antitumor kit, and antitumor agent used in combination with cytarabine
WO2020109625A1 (en) 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma
BR112021012305A2 (pt) 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas
EP4034084B1 (en) 2019-09-27 2025-11-05 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
US20230285364A1 (en) 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도

Similar Documents

Publication Publication Date Title
JP2020517616A5 (cg-RX-API-DMAC7.html)
JP2022515198A5 (cg-RX-API-DMAC7.html)
JP2021522166A5 (cg-RX-API-DMAC7.html)
JP2019518741A5 (cg-RX-API-DMAC7.html)
JP2023520333A5 (cg-RX-API-DMAC7.html)
JP2020007311A5 (cg-RX-API-DMAC7.html)
JP2019527202A5 (cg-RX-API-DMAC7.html)
JP2016506916A5 (cg-RX-API-DMAC7.html)
JP2019535744A5 (cg-RX-API-DMAC7.html)
RU2020102453A (ru) Фармацевтические композиции
JP2019529444A5 (cg-RX-API-DMAC7.html)
JP2019535746A5 (cg-RX-API-DMAC7.html)
JP2019517487A5 (cg-RX-API-DMAC7.html)
RU2015143717A (ru) 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
EP3411121B1 (en) Glucose conjugates of triptolide, analogs and uses thereof
JP2016503414A5 (cg-RX-API-DMAC7.html)
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
JP6002835B2 (ja) 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JP2024513505A5 (cg-RX-API-DMAC7.html)
JP2024532845A5 (cg-RX-API-DMAC7.html)
RU2016147654A (ru) Соединения для лечения рака
JP2019506392A5 (cg-RX-API-DMAC7.html)
CN114728994A (zh) 芳基磷氧类化合物及其用途
RU2011134283A (ru) Имидазотиазольные производные, имеющие пролиновую циклическую структуру